A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-World Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B

Trial Profile

A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-World Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Efmoroctocog alfa (Primary) ; Eftrenonacog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Therapeutic Use
  • Acronyms PREVENT
  • Sponsors Swedish Orphan Biovitrum
  • Most Recent Events

    • 04 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 21 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top